Estimating Utility Values Using the Duchenne Muscular Dystrophy-Quality of Life Measure (DMD-QOL): A New Preference-Based Measure for Duchenne Muscular Dystrophy

Author(s)

Bever A1, Filipovic Audhya I2, Szabo S1, Jayasinghe P1, Feeny D3, Neumann P4, Malone DC5, Iannaccone ST6, Gooch KL2
1Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada, 2Sarepta Therapeutics, Cambridge, MA, USA, 3McMaster University, Hamilton, ON, Canada, 4Tufts Medical Center, Boston, MA, USA, 5The University of Utah, Salt Lake City, UT, USA, 6University of Texas Southwestern Medical Center, Dallas, TX, USA

Presentation Documents

OBJECTIVES: The DMD-QoL is a novel disease-specific preference-based measure (PBM) used to estimate patient utility. This study examined how DMD patient utility values estimated using the DMD-QoL differ to utilities measured via the generic PBM, the Health Utilities Index (HUI).

METHODS: Sixty-three individuals with DMD were recruited through a US-based advocacy organization. Patients 12-40 years of age self-reported current health status and completed the DMD-QoL and HUI. DMD-QoL attributes include mobility, hand function, difficulty breathing, pain, tiredness, worry, participation, and feeling good about oneself. The HUI categorizes health status according to two systems; the HUI2 is presented here, and considers sensation, mobility, emotion, cognition, self-care, pain, and fertility (optional). Median (interquartile, IQR) DMD-QoL and HUI utility values were estimated for DMD-relevant progressive health states.

RESULTS: Mean (standard deviation, SD) patient age was 14.9 (6.9) years and 70% were non-ambulatory. Median (IQR) DMD-QoL utility values ranged from 0.77 (0.73-0.86) for ambulatory individuals with preserved upper limb function (n=10), 0.69 (0.58-0.82) for non-ambulatory with mildly impaired upper limb function (n=16), and 0.20 (-0.02-0.41) for non-ambulatory with loss of upper limb function, symptomatic cardiomyopathy, and nighttime/daytime ventilation (n=2). Median (IQR) HUI2 utilities for these health states were 0.96 (0.86-0.99); 0.51 (0.44-0.55); and 0.32 (0.23-0.42). While DMD-QoL mobility and hand function scores are lower with disease progression, this drop in scores was not observed until loss of upper limb function. Mobility and self-care were the HUI2 attributes reflecting the greatest impact, with a worsening of levels observed earlier in DMD progression compared to on the DMD-QoL.

CONCLUSIONS: Compared to HUI2, DMD-QoL utility values remained relatively stable across health states until loss of upper limb function precipitated lower values. Mobility was a driver of utility in both instruments, yet differences in scores may reflect the DMD-QoL’s broader conceptualization of mobility. Future research should compare findings to other commonly-used PBMs.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)

Code

PCR230

Topic

Patient-Centered Research

Topic Subcategory

Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes

Disease

Genetic, Regenerative & Curative Therapies, Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal), Personalized & Precision Medicine

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×